BOSTON, Massachusetts — August 8, 2025 — Leads & Copy — Compass Therapeutics, Inc. (Nasdaq: CMPX) will release its financial results for the quarter ended June 30, 2025, and host a webcast and conference call on Monday, August 11, 2025, at 8:00 a.m. ET, to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726.
The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a pipeline of novel product candidates designed to target multiple critical biological pathways for an effective anti-tumor response.
Call Details:
Date: Monday, August 11, 2025
Time: 8:00 AM ET
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1727543&tp_key=955a2c2f4d
Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Conference ID)
Virtual/Replay availability: A replay will be archived for 90 days on Compass’ Events page.
Investor Contact:
ir@compasstherapeutics.com
Media Contact:
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
Source: Compass Therapeutics
